A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.

@article{Lubner2015AP1,
  title={A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.},
  author={Sam Joseph Lubner and Jacqueline A. Mullvain and Scott B. Perlman and Michael J Pishvaian and Joanne Mortimer and Katherine Oliver and Jennifer Heideman and Lance T. Hall and Jamey P. Weichert and Glenn X Liu},
  journal={Cancer investigation},
  year={2015},
  volume={33 10},
  pages={483-9}
}
This study explores the imaging and therapeutic properties of a novel radiopharmaceutical, (131)I-CLR1404. Phase 1a data demonstrated safety and tumor localization by SPECT-CT. This 1b study assessed safety, imaging characteristics, and possible antineoplastic properties and provided further proof-of-concept of phospholipid ether analogues' retention within… CONTINUE READING